CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicUpdates on the Management of Hematologic Malignancies from SOHO Italy: Educational Insights and Clinical PerspectivesView all 8 articles
Polatuzumab Vedotin Plus Rituximab with Chemotherapy in Newly Diagnosed Pediatric Stage IV Burkitt Lymphoma: Case Report Highlighting Early Complete Remission
Provisionally accepted
- Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Although pediatric Burkitt lymphoma is considered curable, some patients still have a poor prognosis. Lack of early or complete response is an adverse prognostic factor. Therefore, improving patients' sensitivity to initial treatment and achieving complete remission early are crucial for enhancing efficacy. Herein, we report two cases of children with newly diagnosed clinical stage IV Burkitt lymphoma who achieved early complete metabolic remission after only two cycles of treatment with polatuzumab vedotin plus rituximab combined with chemotherapy. Notably, this represents the first reported application of polatuzumab vedotin in pediatric patients with newly diagnosed Burkitt lymphoma.
Keywords: Burkitt Lymphoma, pediatric, Polatuzumab vedotin, early complete remission, Casereport
Received: 13 Aug 2025; Accepted: 27 Oct 2025.
Copyright: © 2025 Sun, Deng, Zhang, Chen, Zhang and Zuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wenli Zuo, wenlizuoqq@aliyun.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.